Published in Mov Disord on June 15, 2010
α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest (2011) 3.53
Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol (2010) 3.34
Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J (2012) 2.36
100 years of Lewy pathology. Nat Rev Neurol (2012) 2.15
Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci (2015) 1.53
Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc Natl Acad Sci U S A (2014) 1.44
Cell therapeutics in Parkinson's disease. Neurotherapeutics (2011) 1.32
Intercellular (mis)communication in neurodegenerative disease. Neuron (2012) 1.31
A deadly spread: cellular mechanisms of α-synuclein transfer. Cell Death Differ (2011) 1.27
Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacology (2011) 1.21
Transfer of host-derived α synuclein to grafted dopaminergic neurons in rat. Neurobiol Dis (2011) 1.21
Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS One (2012) 1.15
Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med (2012) 1.06
Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies. Brain (2015) 1.03
Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein. Acta Neuropathol Commun (2013) 1.01
α-Synuclein: the long distance runner. Brain Pathol (2013) 0.99
Cell-based therapies for Parkinson disease—past insights and future potential. Nat Rev Neurol (2015) 0.97
Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment. Autophagy (2014) 0.96
Aggregation and neurotoxicity of recombinant α-synuclein aggregates initiated by dimerization. Mol Neurodegener (2013) 0.94
Moving stem cells to the clinic: potential and limitations for brain repair. Neuron (2015) 0.94
Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc Natl Acad Sci U S A (2016) 0.94
Interaction between α-synuclein and other proteins in neurodegenerative disorders. ScientificWorldJournal (2011) 0.89
Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology. J Neurochem (2016) 0.88
Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease. J Exp Med (2016) 0.87
Studies of lipopolysaccharide effects on the induction of α-synuclein pathology by exogenous fibrils in transgenic mice. Mol Neurodegener (2015) 0.87
Targeting heat shock proteins to modulate α-synuclein toxicity. Ther Adv Neurol Disord (2014) 0.84
The Interplay between Alpha-Synuclein Clearance and Spreading. Biomolecules (2015) 0.84
Cell viability and dopamine secretion of 6-hydroxydopamine-treated PC12 cells co-cultured with bone marrow-derived mesenchymal stem cells. Neural Regen Res (2012) 0.82
Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapy. Clin Dev Immunol (2013) 0.81
Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives. Int J Mol Sci (2016) 0.80
Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci (2017) 0.79
Primary cilia and autophagic dysfunction in Huntington's disease. Cell Death Differ (2015) 0.78
Treatment of Parkinson's disease using cell transplantation. Philos Trans R Soc Lond B Biol Sci (2015) 0.78
Does a prion-like mechanism play a major role in the apparent spread of α-synuclein pathology? Alzheimers Res Ther (2012) 0.78
Therapeutic application of neural stem cells and adult neurogenesis for neurodegenerative disorders: regeneration and beyond. Eur J Neurodegener Dis (2015) 0.77
Critical aspects of clinical trial design for novel cell and gene therapies. Parkinsons Dis (2011) 0.76
Comparison of Human Primary with Human iPS Cell-Derived Dopaminergic Neuron Grafts in the Rat Model for Parkinson's Disease. Stem Cell Rev (2016) 0.76
How strong is the evidence that Parkinson's disease is a prion disorder? Curr Opin Neurol (2016) 0.75
More than a Rumor Spreads in Parkinson's Disease. Front Hum Neurosci (2016) 0.75
The future of stem cells in neurodegenerative disorders of the central nervous system. CMAJ (2011) 0.75
Repairing the Aged Parkinsonian Striatum: Lessons from the Lab and Clinic. J Clin Cell Immunol (2016) 0.75
Metal Dyshomeostasis and Their Pathological Role in Prion and Prion-Like Diseases: The Basis for a Nutritional Approach. Front Neurosci (2017) 0.75
α-Synuclein and nonhuman primate models of Parkinson's disease. J Neurosci Methods (2015) 0.75
Merging DBS with viral vector or stem cell implantation: "hybrid" stereotactic surgery as an evolution in the surgical treatment of Parkinson's disease. Mol Ther Methods Clin Dev (2016) 0.75
Exploring Braak's Hypothesis of Parkinson's Disease. Front Neurol (2017) 0.75
Novel animal model defines genetic contributions for neuron-to-neuron transfer of α-synuclein. Sci Rep (2017) 0.75
The spread of prion-like proteins by lysosomes and tunneling nanotubes: Implications for neurodegenerative diseases. J Cell Biol (2017) 0.75
Basic science in Parkinson's disease: its impact on clinical practice. J Neurol (2011) 0.75
Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med (2002) 10.10
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med (2008) 6.90
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol (2012) 5.18
Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci U S A (2003) 5.09
Direct conversion of human fibroblasts to dopaminergic neurons. Proc Natl Acad Sci U S A (2011) 4.81
The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron (2003) 4.49
α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest (2011) 3.53
Caspase signalling controls microglia activation and neurotoxicity. Nature (2011) 3.44
TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc Natl Acad Sci U S A (2013) 3.33
Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron (2002) 3.15
Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci (2002) 3.12
Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci (2002) 2.93
Persistent production of neurons from adult brain stem cells during recovery after stroke. Stem Cells (2005) 2.88
A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med (2008) 2.78
Forebrain ependymal cells are Notch-dependent and generate neuroblasts and astrocytes after stroke. Nat Neurosci (2009) 2.74
The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol (2013) 2.65
New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell (2008) 2.61
Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci (2008) 2.51
Generation of induced neurons via direct conversion in vivo. Proc Natl Acad Sci U S A (2013) 2.51
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain (2007) 2.49
Environment matters: synaptic properties of neurons born in the epileptic adult brain develop to reduce excitability. Neuron (2006) 2.38
Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. Cell Rep (2012) 2.31
Improving outcome after stroke: overcoming the translational roadblock. Cerebrovasc Dis (2008) 2.26
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
Myeloid and lymphoid contribution to non-haematopoietic lineages through irradiation-induced heterotypic cell fusion. Nat Cell Biol (2008) 2.17
Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain (2005) 2.06
Comparison of accuracy and precision between frame-based and frameless stereotactic navigation for deep brain stimulation electrode implantation. Stereotact Funct Neurosurg (2007) 2.00
Long-term neuroblast migration along blood vessels in an area with transient angiogenesis and increased vascularization after stroke. Stroke (2007) 1.98
A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3. J Neuropathol Exp Neurol (2007) 1.95
Cell therapy in Parkinson's disease. NeuroRx (2004) 1.93
Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci U S A (2003) 1.92
Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J Neurosci (2006) 1.91
Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. J Neurosci (2009) 1.89
Long-term accumulation of microglia with proneurogenic phenotype concomitant with persistent neurogenesis in adult subventricular zone after stroke. Glia (2009) 1.86
Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol (2009) 1.83
The influence of induced hypothermia and delayed prognostication on the mode of death after cardiac arrest. Resuscitation (2012) 1.82
Neurogenesis after ischaemic brain insults. Curr Opin Neurobiol (2003) 1.80
Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci Transl Med (2010) 1.78
Stroke research priorities for the next decade--A representative view of the European scientific community. Cerebrovasc Dis (2006) 1.75
Red flags for multiple system atrophy. Mov Disord (2008) 1.75
Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci (2002) 1.74
Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. Lancet Neurol (2013) 1.72
Involvement of Ngn2, Tbr and NeuroD proteins during postnatal olfactory bulb neurogenesis. Eur J Neurosci (2009) 1.71
Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. J Neurosci (2005) 1.67
Multicenter study on deep brain stimulation in Parkinson's disease: an independent assessment of reported adverse events at 4 years. Mov Disord (2008) 1.65
Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol (2003) 1.64
Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J Biol Chem (2002) 1.64
Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat Neurosci (2004) 1.61
CD133 is not present on neurogenic astrocytes in the adult subventricular zone, but on embryonic neural stem cells, ependymal cells, and glioblastoma cells. Cancer Res (2007) 1.58
Efficient production of mesencephalic dopamine neurons by Lmx1a expression in embryonic stem cells. Proc Natl Acad Sci U S A (2009) 1.57
Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res (2005) 1.56
Cross-talk between neural stem cells and immune cells: the key to better brain repair? Nat Neurosci (2012) 1.55
Clinicopathological concordance in dementia diagnostics. Am J Geriatr Psychiatry (2009) 1.54
L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis (2002) 1.54
Are synucleinopathies prion-like disorders? Lancet Neurol (2010) 1.54
Cell transplantation in Parkinson's disease: how can we make it work? Trends Neurosci (2005) 1.51
Is aqueductal stroke volume, measured with cine phase-contrast magnetic resonance imaging scans useful in predicting outcome of shunt surgery in suspected normal pressure hydrocephalus? Neurosurgery (2007) 1.50
Stem cells: hype or hope? Drug Discov Today (2002) 1.48
Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts. Eur J Nucl Med Mol Imaging (2006) 1.46
Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci (2007) 1.42
Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons. Proc Natl Acad Sci U S A (2012) 1.40
α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med (2012) 1.40
No evidence for new dopaminergic neurons in the adult mammalian substantia nigra. Proc Natl Acad Sci U S A (2004) 1.39
GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease. Brain (2011) 1.38
Stroke-induced neurogenesis in aged brain. Stroke (2005) 1.38
Neural stem and progenitor cells retain their potential for proliferation and differentiation into functional neurons despite lower number in aged brain. J Neurosci (2009) 1.37
Critical issues of clinical human embryonic stem cell therapy for brain repair. Trends Neurosci (2008) 1.37
Inflammation regulates functional integration of neurons born in adult brain. J Neurosci (2008) 1.35
Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord (2010) 1.34
Human-induced pluripotent stem cells form functional neurons and improve recovery after grafting in stroke-damaged brain. Stem Cells (2012) 1.34
Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Mov Disord (2013) 1.34
Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet (2002) 1.33
The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx (2005) 1.33
Orexin loss in Huntington's disease. Hum Mol Genet (2004) 1.33
Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells. Stem Cells (2012) 1.32
Cell therapeutics in Parkinson's disease. Neurotherapeutics (2011) 1.32
Migration patterns and phenotypic differentiation of long-term expanded human neural progenitor cells after transplantation into the adult rat brain. Brain Res Dev Brain Res (2002) 1.32
Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J Neurosci (2005) 1.31
Quantification of myelin loss in frontal lobe white matter in vascular dementia, Alzheimer's disease, and dementia with Lewy bodies. Acta Neuropathol (2010) 1.31
Forebrain acetylcholine regulates adult hippocampal neurogenesis and learning. Neurobiol Aging (2005) 1.31
Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice. Acta Neuropathol (2013) 1.30
The adult human brain harbors multipotent perivascular mesenchymal stem cells. PLoS One (2012) 1.30
Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J Clin Invest (2008) 1.29
MANF is widely expressed in mammalian tissues and differently regulated after ischemic and epileptic insults in rodent brain. Mol Cell Neurosci (2008) 1.29
Regulation of stem cell therapies under attack in Europe: for whom the bell tolls. EMBO J (2013) 1.28